Tricida, Inc., is a pre-clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class therapeutics. Tricida's lead program is TRC101, a chronic treatment for complications of renal disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/04/15 | $30,000,000 | Series B |
Limulus Venture Partners OrbiMed Advisors Sibling Capital | undisclosed |
| 07/25/16 | $55,000,000 | Series C |
Limulus Venture Partners Longitude Capital OrbiMed Advisors Sibling Capital Vivo Ventures | undisclosed |
| 11/08/17 | $57,500,000 | Series D |
Cormorant Asset Management Limulus Venture Partners Longitude Capital OrbiMed Advisors Sibling Capital Venrock Vivo Capital Wellington Management Company | undisclosed |
